People · Operator
Named in public records as an officer, director or promoter · active 2010–2024 · Biotechnology, AI / ML, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Exosome Diagnostics, Inc. | — | Biotechnology | Series B | $90.9M | $1.2B | 2010 |
| LungLife AI, Inc. | — | AI / ML | Series B | $68.4M | $2.9M | 2017 |
| Verici DX plc | — | Other Health Care | Seed | $2.7M | $58.2M | 2020 |
James McCullough at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James McCullough on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Sara Barrington | 3 | 3 |
| David Anderson | 1 | 21 |
| Michael Pfau | 1 | 7 |
| Michael E. Pfau | 1 | 6 |
| Alan Heeger | 1 | 5 |
| Paul Anderson | 1 | 5 |
| Amit Munshi | 1 | 5 |
| Paul Billings | 1 | 5 |
| William Kelly | 1 | 5 |
| Georg Nebgen | 1 | 5 |
| David Okrongly | 1 | 4 |
| John Boyce | 1 | 4 |
| Erik Lium | 1 | 3 |
| Paul Meyer | 1 | 2 |
| Kapil Dhingra | 1 | 2 |
| Thomas McLain | 1 | 2 |
| Geert-Jan Mulder | 1 | 2 |
| Joseph Boystak | 1 | 2 |
| Simon Raab | 1 | 2 |
| Frederick Gluck | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.